Latest / Pharmacy Podcast Network / ASX 25: Access to Pharmacy in Las Vegas | Part One sponsored by DrFirst
Transcript
- 0:05Speaker 1: You are listening to the global network of podcasters dedicated
- 0:09Speaker 1: to the pharmacy profession. Welcome to the Pharmacy podcast Network.
- 0:28Speaker 2: Welcome to Part one of our special three part series
- 0:30Speaker 2: from the heart of Las Vegas at ASSEMBIA twenty twenty five,
- 0:33Speaker 2: the premier Access to Pharmacy Conference, bringing together innovators, decision makers,
- 0:38Speaker 2: and visionaries from across the healthcare landscape. Over the next
- 0:41Speaker 2: few episodes, we're taking you inside the action with exclusive
- 0:45Speaker 2: interviews from exhibitors and attendees who are shaping the future
- 0:48Speaker 2: of patient access, pharmacy, benefit design, and healthcare delivery. In
- 0:53Speaker 2: today's episode, we'll kick things off on the show floor,
- 0:55Speaker 2: exploring what's new, what's next, and what's making the biggest
- 0:59Speaker 2: impact here firsthand from exhibitors debuting new solutions and attendees
- 1:03Speaker 2: sharing their perspective on where the industry is heading.
- 1:06Speaker 3: Whether you made it to Las Vegas or this is
- 1:08Speaker 3: your first.
- 1:08Speaker 2: Look into ASSEMBIA twenty twenty five, we're bringing you key
- 1:11Speaker 2: moments from the conference. Part one of the Access to
- 1:14Speaker 2: Pharmacy twenty twenty five conference. Post show is sponsored by
- 1:17Speaker 2: Doctor First.
- 1:25Speaker 4: Doctor First.
- 1:26Speaker 5: Here at ASSEMBIA twenty twenty five, they say access to
- 1:30Speaker 5: Pharmacy twenty five calling.
- 1:32Speaker 4: It is so good to see you.
- 1:33Speaker 3: It's always good to see you. Thanks for having me.
- 1:35Speaker 5: This is becoming kind of a tradition of ours. Your
- 1:38Speaker 5: insights here are important to us because technology is moving
- 1:42Speaker 5: at a lightning fast pace. So I kind of want
- 1:45Speaker 5: to tag in and check up with Doctor First and
- 1:47Speaker 5: really find out what's going on and more specifically what's
- 1:51Speaker 5: happening in the specialty pharmacy space.
- 1:53Speaker 3: Yeah, it's a busy space. You know. Three out of
- 1:56Speaker 3: every four drugs in development right now are deemed specialty medication.
- 2:00Speaker 3: And so for Doctor First, a company that specializes in
- 2:04Speaker 3: end to end medication management, we would be remiss if
- 2:08Speaker 3: we weren't trying to ease the friction in the specialty
- 2:12Speaker 3: medication process, and I mean the friction for all those involved,
- 2:16Speaker 3: so not just for the patient, but also for the providers.
- 2:19Speaker 3: And I think that really starts with transparency. I think
- 2:23Speaker 3: it is very difficult scene to navigate right now, and
- 2:27Speaker 3: the more that we can do to lift and peel
- 2:29Speaker 3: back the layers on behalf of our providers and then
- 2:32Speaker 3: on behalf of our patients subsequently, is time well spent.
- 2:37Speaker 3: And so you're going to see Doctor First really doubling
- 2:40Speaker 3: down in the specialty space, particularly around of course, the
- 2:45Speaker 3: pain of prior authorization. And one of the things that
- 2:48Speaker 3: we're really focused on is specially medications that are not
- 2:53Speaker 3: only falling under your prescription benefit, but also those high
- 2:57Speaker 3: dollars specialty meds that are part of your meta cold benefit.
- 3:01Speaker 3: So think of infusions and things that need to be
- 3:03Speaker 3: given in clinical settings as opposed to getting picked up
- 3:06Speaker 3: at the drug store.
- 3:08Speaker 5: I think of the roadblocks in the realm of specialty pharmacy.
- 3:13Speaker 5: There are a lot We're talking about technology platforms and
- 3:15Speaker 5: prior authorizations and workflow and product accessibility.
- 3:21Speaker 4: So doctor First is really.
- 3:22Speaker 5: Becoming this streamline mechanism technology provider. How what other tools
- 3:28Speaker 5: are are the doctor First clients using in the specialty
- 3:33Speaker 5: space to really help things keep going?
- 3:35Speaker 3: Yeah, you know, right now, some of the things that
- 3:39Speaker 3: we're really focused in on are actually quite simple, and
- 3:43Speaker 3: sometimes simple is the best, but guiding the provider to
- 3:48Speaker 3: do the right thing at the right moment, and some
- 3:51Speaker 3: of the examples these sound so simple, but they're actually
- 3:54Speaker 3: quite complex behind the scenes. But you know, if you
- 3:57Speaker 3: come to see me and you need a specialty medication
- 3:59Speaker 3: and I'm like sure, you know, let's let's go ahead
- 4:01Speaker 3: and write for that, and your default pharmacy is, you know,
- 4:05Speaker 3: x y Z right down the street. Chances are specialty
- 4:09Speaker 3: medication might not be able to be filled there limited
- 4:12Speaker 3: distribution things like that. Well, our platform can actually tell
- 4:16Speaker 3: the doctor that in real time. You know, you have
- 4:20Speaker 3: this setup to go to x y Z, but actually
- 4:22Speaker 3: there's only three pharmacies in America that can fill this,
- 4:25Speaker 3: and here's where they are, and click here to change
- 4:28Speaker 3: the default pharmacy for that one drug without changing the
- 4:31Speaker 3: default pharmacy for all similar You know, a lot of
- 4:36Speaker 3: times you can avoid a prior authorization simply by attaching
- 4:39Speaker 3: an ICD ten code. People don't know that. Doctors aren't
- 4:42Speaker 3: going to do that unless they know there's value there,
- 4:45Speaker 3: and so we have the ability with our platform to
- 4:47Speaker 3: know when that's needed, when that's not, when it's going
- 4:50Speaker 3: to influence. And again, all of these forms of decision support.
- 4:54Speaker 3: These gentle nudges are non obstructive.
- 4:57Speaker 6: They are a.
- 4:58Speaker 3: Little slide outs to the side, their little changes in
- 5:01Speaker 3: color or fonts, just to let the doctor or the
- 5:04Speaker 3: prescriber know there's action that could be taken here. But
- 5:08Speaker 3: just like any good decision support is like the painted
- 5:11Speaker 3: lines on a highway. You know, the doctor the prescriber
- 5:15Speaker 3: uses those lines to know where they're going. But if
- 5:18Speaker 3: they need to, you know, cross those lines to go
- 5:20Speaker 3: somewhere else or do something different, they can. So they're
- 5:23Speaker 3: not meant to be hard and fast guardrails. They are
- 5:27Speaker 3: suggestions and that's to me, that's I've spent two decades
- 5:31Speaker 3: on decision support and that's the key to good decision
- 5:34Speaker 3: support is actionability and flexibility.
- 5:37Speaker 5: You've been in the space long enough not to make
- 5:39Speaker 5: you sound old, Colin, but you've been around to see
- 5:42Speaker 5: things shifting and changing, especially in the more difficult handling.
- 5:46Speaker 4: Of specially meds.
- 5:48Speaker 5: Doctor First has been keeping up with those kinds of
- 5:51Speaker 5: changes for years. Where are we going with AI and
- 5:55Speaker 5: decision support and clinical support? Where do you see AI
- 5:59Speaker 5: kind of enhancing the realm of specialty fires?
- 6:01Speaker 3: Yeah, I've never seen anything move this quickly two plus
- 6:05Speaker 3: decades and informatics and a couple of the talks today.
- 6:09Speaker 3: Of course, we're centered around AI, really really good speakers here.
- 6:14Speaker 3: And you know, Doctor First is you know, first of all,
- 6:18Speaker 3: as a company, we are embracing an AI first culture,
- 6:22Speaker 3: So we want to use AI to augment all of
- 6:24Speaker 3: the things that we do when it's responsible to do
- 6:26Speaker 3: so in our day to day work, you know, summarizations,
- 6:33Speaker 3: you know, I think we're all getting used to the
- 6:34Speaker 3: meeting bots that help you figure out to dos and
- 6:38Speaker 3: action items. But on the platform side, on the on
- 6:41Speaker 3: the patient facing, provider facing side, we are we are
- 6:45Speaker 3: all in on AI for automating as much of this
- 6:48Speaker 3: as we can on behalf of the prescriber, so particularly
- 6:52Speaker 3: prior authorization. We've talked about this before, but about a
- 6:56Speaker 3: year ago we acquired a platform called mind Shift which
- 7:00Speaker 3: helps us with that total benefits management, the medical and
- 7:03Speaker 3: the pharmaceutical benefit and they had been already leveraging AI
- 7:08Speaker 3: for automation, and it's only going to get it's only
- 7:11Speaker 3: going to improve. One of the things that you're going
- 7:14Speaker 3: to see here this week at ASSEMBIA is this notion
- 7:17Speaker 3: of agentic AI or bots and stringing together bots that
- 7:23Speaker 3: are specific for a very specific use case and stringing
- 7:28Speaker 3: them together so that you can sort of follow the
- 7:32Speaker 3: thread of this complex tapestry around specialty medications. And so
- 7:36Speaker 3: this is really exciting, you know, for the industry, but
- 7:39Speaker 3: also for doctor first wanting to be a leader in
- 7:43Speaker 3: this end and medication management space.
- 7:45Speaker 5: All right, so we're at Asembia. We're here concentrating on
- 7:50Speaker 5: the business of specialty pharmacy. There's lots of specialty pharmacists
- 7:55Speaker 5: that are probably listening to the post show what do
- 7:57Speaker 5: you want to say to them and helping them to
- 8:00Speaker 5: understand better of how Doctor First is a partner in
- 8:03Speaker 5: specialty pharmacy.
- 8:04Speaker 3: Yeah, we are partnered with pretty much every node in
- 8:10Speaker 3: the medication journey already, so we have real estate that
- 8:16Speaker 3: faces the provider, the ability to influence help them do
- 8:19Speaker 3: the right thing. We have connections with pharmacies themselves. We're
- 8:24Speaker 3: actually working on novel connections to help improve the entire
- 8:28Speaker 3: prescription process. We of course have partnerships with pharmaceutical companies
- 8:32Speaker 3: life sciences so that we can help get the right
- 8:35Speaker 3: kind of education not only in front of the provider,
- 8:38Speaker 3: but also in front of the patient. And then we
- 8:40Speaker 3: connect directly to the patient through our platform to help
- 8:43Speaker 3: them with adherents, education, savings opportunities, because we really want
- 8:48Speaker 3: to overcome those barriers. I think people have heard me
- 8:51Speaker 3: say this many times, but my mission and the mission
- 8:54Speaker 3: for doctor First is to get patients on and keep
- 8:57Speaker 3: them on appropriate therapy, and my submission, though it's probably
- 9:03Speaker 3: one A, is to make that experience as joyful as possible.
- 9:07Speaker 3: And I know that sounds ridiculous, but there's no reason
- 9:11Speaker 3: this can't actually be a positive experience for all those involved.
- 9:14Speaker 3: It's time to peel back the layers and really get
- 9:18Speaker 3: transparency in front of all of this.
- 9:20Speaker 5: I also want to shift gears and talk for just
- 9:23Speaker 5: a second for our listeners out there who may not know.
- 9:26Speaker 5: Talk to us about timely and how that is now
- 9:29Speaker 5: intricate and how special that is. Has an extension of
- 9:32Speaker 5: the doctor first portfolio.
- 9:33Speaker 3: Yeah, that's this notion of patient engagement in almost real
- 9:38Speaker 3: time from when a prescription is sent or a pharmacy
- 9:42Speaker 3: recedes it. It's the ability to send a personalized SMS
- 9:47Speaker 3: message to that patient that delivers an app like experience.
- 9:52Speaker 3: So we don't make them go to a separate app
- 9:54Speaker 3: store or a separate username and login. They verify with
- 9:58Speaker 3: their data birth and then boom, you've got this app
- 10:01Speaker 3: like experience which is very clean, and it offers what
- 10:04Speaker 3: I consider the three biggest barriers to patient adherence. We're
- 10:07Speaker 3: going to conquer those patient education. You know, I'm going
- 10:11Speaker 3: to help tell you why this MET is important or
- 10:13Speaker 3: what you can expect. Two is probably the most important,
- 10:17Speaker 3: which is cost savings opportunities. You know, once that copaid
- 10:21Speaker 3: gets up in that you know, seventy five to one
- 10:23Speaker 3: hundred dollars range, the compliance adherence really drops off. And
- 10:26Speaker 3: then the third one is just simple reminders. You know, hey,
- 10:31Speaker 3: your prescription was just sent to X, Y Z, and
- 10:34Speaker 3: this is the location for it, and here's the phone
- 10:37Speaker 3: number that you can click on if you want to
- 10:39Speaker 3: know more. And then we can reinforce these behaviors. You know,
- 10:42Speaker 3: if a prescription hasn't been picked up five days later,
- 10:46Speaker 3: we can detect that setting other message, you know, so
- 10:48Speaker 3: simple things, simple interfaces, and really doing it at the
- 10:54Speaker 3: at the moment of inception or this notion of that
- 10:58Speaker 3: care of met just occurred. Let's reinforce what the care
- 11:02Speaker 3: plan was, what the medications were, right then and there
- 11:05Speaker 3: so that we can really get this behavior and grained
- 11:08Speaker 3: into our patients.
- 11:09Speaker 4: I love it.
- 11:10Speaker 7: I love it.
- 11:10Speaker 5: What do you want to say to the specialty pharmacists
- 11:14Speaker 5: listening right now who want to move forward, want to
- 11:18Speaker 5: know more?
- 11:19Speaker 4: What do you say to them?
- 11:21Speaker 5: And taking steps to evaluate how doctor first and the
- 11:24Speaker 5: systems that you have, the programs that you have could
- 11:26Speaker 5: fit into their workflow and their pharmacy.
- 11:28Speaker 3: Yeah, first and foremost, reach out, reach out while we're here,
- 11:32Speaker 3: that we have a large team presence here. If not,
- 11:36Speaker 3: find me on LinkedIn or even x formerly Twitter, whatever
- 11:39Speaker 3: we're calling it these days. And you know, doctor First
- 11:44Speaker 3: is in a unique position to help. I will say
- 11:47Speaker 3: that to the specialty pharmacies pharmaceutical companies out there, this
- 11:52Speaker 3: notion of end to end management and touching all of
- 11:55Speaker 3: the various nodes is a very unique position for us
- 11:58Speaker 3: with the ability to influence behaviors on all fronts.
- 12:02Speaker 5: Colin Banas with doctor First here at Assembia twenty twenty five,
- 12:07Speaker 5: also a sponsor of the Pharmacy Podcast Networks press coverage.
- 12:11Speaker 5: We are so excited to work with you, Colin. Thank
- 12:14Speaker 5: you so much for this time.
- 12:15Speaker 3: Oh I love it. Todd, thanks for having me.
- 12:22Speaker 8: This episode of the Pharmacy Podcast Network is brought to
- 12:25Speaker 8: you by doctor First, where smarter workflows power better patient
- 12:29Speaker 8: outcomes for pharmacies. That means fewer headaches like prescriptions that
- 12:33Speaker 8: can't be filled because they need a prior authorization, they're
- 12:37Speaker 8: missing clinical context. The NDC doesn't match the description or surprise,
- 12:42Speaker 8: it's a limited distribution drug.
- 12:44Speaker 6: You know, the headaches that happen next, calls, emails, faxes, the.
- 12:47Speaker 9: Never ending back and forth.
- 12:48Speaker 1: It wastes time, delays care, and frustrates everyone, your staff, physicians,
- 12:53Speaker 1: and patients.
- 12:53Speaker 3: They all deserve better.
- 12:55Speaker 8: Better is doctor First. We flipped the script with a
- 12:58Speaker 8: modern approach built for real time collapse and a smooth
- 13:01Speaker 8: path from prescription to adherents. Powered by the nation's largest
- 13:04Speaker 8: medication management network. Doctor First clears prescription roadblocks before they
- 13:08Speaker 8: reach your pharmacy, so you get clean, actionable prescriptions ready
- 13:12Speaker 8: to fill. No delays, no back and forth, just smoother workflows,
- 13:16Speaker 8: more time for pharmacists to practice at the top of
- 13:19Speaker 8: their license, and your patients start therapy faster.
- 13:22Speaker 9: Let's end your headaches and clear the path to care together.
- 13:25Speaker 8: See how at doctor first dot com slash Pharmacy.
- 13:32Speaker 5: Drew. We are at access twenty twenty five axs.
- 13:37Speaker 4: I guess that's access, isn't it sure?
- 13:40Speaker 5: They say access, Yeah, Access to Pharmacy twenty twenty five Assembia.
- 13:45Speaker 5: I say assembia. Actually, as I started coming here when
- 13:48Speaker 5: it was Armada Health. That shows you how old I
- 13:51Speaker 5: am well.
- 13:52Speaker 7: In classic healthcare fashion. We needed more acronyms. So there
- 13:56Speaker 7: you go.
- 13:57Speaker 5: It's so good that you're here. We appreciate Doctor First
- 14:00Speaker 5: support of this event. Drew, tell our listeners a little
- 14:03Speaker 5: bit about yourself before we get into today's interview.
- 14:06Speaker 3: Yeah.
- 14:06Speaker 10: Sure, obviously. My name is Drew. I've been with doctor
- 14:10Speaker 10: First for fifteen years.
- 14:12Speaker 7: I spent about a decade of that time working integrating
- 14:16Speaker 7: our e prescribing and medication management solutions into EHRs, so
- 14:21Speaker 7: focused a lot on getting to know a provider workflow,
- 14:24Speaker 7: getting to know the ins and outs of you know,
- 14:28Speaker 7: software company business development, and towards the latter end of that,
- 14:32Speaker 7: started focusing very heavily on our patient applications and now
- 14:37Speaker 7: really am at a corporate level looking at specialty and
- 14:39Speaker 7: trying to figure out how to combine those assets and
- 14:42Speaker 7: how to solve some problems that are just written from us.
- 14:45Speaker 5: Well, there's a lot of problems. I mean, let's let
- 14:48Speaker 5: we're not going to sugarcoat it. I mean the world
- 14:50Speaker 5: of specialty pharmacy is so complex. So when we have
- 14:54Speaker 5: organizations like doctor First who give us tools to keep
- 14:58Speaker 5: things on track. Shut out to Colin Bannis, who was
- 15:01Speaker 5: on our show, talking about He was saying the painted
- 15:05Speaker 5: lines on the highway when it's when there's a fog
- 15:08Speaker 5: out there and you can't see anything, but you can
- 15:11Speaker 5: see those painted bright yellow lines.
- 15:14Speaker 4: That means you can stay on the road.
- 15:16Speaker 5: And Doctor First is doing that for the patient, physician
- 15:20Speaker 5: and pharmaci's combination with timely and some of the things
- 15:24Speaker 5: that you guys have developed. But what I want to
- 15:26Speaker 5: kind of dig into with you is that friction for
- 15:30Speaker 5: patients and specialty pharmacies. That's the ecosystem that they're living in.
- 15:35Speaker 5: First of all, they just got told that they have
- 15:39Speaker 5: some kind of disease that they have to deal with
- 15:41Speaker 5: for the rest of their life. Now they have to
- 15:43Speaker 5: deal with specialty pharmacy and all the intricacies. Doctor First
- 15:47Speaker 5: steps in and gives us that double yellow line.
- 15:52Speaker 4: To keep us on track. So talk to us a
- 15:54Speaker 4: little bit about that.
- 15:55Speaker 7: Yeah, I mean, I think it's really interesting, right because ultimately,
- 15:59Speaker 7: these patients that to your point, have just been prescribed
- 16:02Speaker 7: to specialty therapy need it the most and for some reason,
- 16:06Speaker 7: and we can get into those reasons, they face.
- 16:09Speaker 10: The most challenges to access those prescriptions.
- 16:12Speaker 7: And so when doctor First looks at it, we kind
- 16:14Speaker 7: of first first step was to lay all the cards
- 16:17Speaker 7: on the table. Right, we have provider workflow that we
- 16:20Speaker 7: can improve, Okay, you can check that box.
- 16:23Speaker 10: Ultimately, the patient needs to.
- 16:25Speaker 7: End up knowing what's happening, knowing what the next best
- 16:28Speaker 7: action is, knowing if they need to do anything to
- 16:31Speaker 7: try and address an issue, and then making sure that
- 16:34Speaker 7: all of this fits into existing specialty pharmacy workflows so
- 16:38Speaker 7: that none of those three parties really have to change
- 16:42Speaker 7: the way they do things. It's more of just the
- 16:45Speaker 7: systems working as they should. And so that's really our
- 16:48Speaker 7: mission is how do we.
- 16:50Speaker 10: How do we keep them doing what.
- 16:52Speaker 7: They're doing today but have the unique challenges of specialty
- 16:57Speaker 7: medications just work.
- 16:59Speaker 10: And that's It'll keep us busy for a while.
- 17:03Speaker 5: I'm sure when I think of what you just said
- 17:05Speaker 5: when you opened up and you're talking about the APIs
- 17:08Speaker 5: that were developed back in the day to the EHR systems,
- 17:12Speaker 5: and then all of a sudden, you have to spit
- 17:13Speaker 5: back information to the pharmacy management system and you have
- 17:17Speaker 5: to communicate with the manufacturer with REMS, reporting data and
- 17:22Speaker 5: all this stuff. Like from a patient's perspective, they don't
- 17:25Speaker 5: see that behind the scenes they don't understand. What they
- 17:28Speaker 5: want to know is when am I getting my medication?
- 17:31Speaker 5: How does this medication affect me? How do I keep
- 17:34Speaker 5: going staying indherent. I think of Timely as a platform
- 17:39Speaker 5: that helps keep things feeling natural for the patient, because
- 17:44Speaker 5: if I start getting texts from a system I'm already
- 17:47Speaker 5: used to.
- 17:47Speaker 4: Texting mobile phones.
- 17:49Speaker 5: Is just part of our of our lives, and now
- 17:52Speaker 5: all of a sudden it's being integrated naturally into my life.
- 17:56Speaker 5: Where now I'm getting information, valuable information.
- 18:00Speaker 4: Where I'm Where is my prescription? Where is my meds?
- 18:03Speaker 4: When is my next dose?
- 18:05Speaker 11: Do?
- 18:05Speaker 4: Or my refill?
- 18:06Speaker 11: Do?
- 18:06Speaker 5: Talk to me a little bit about that and how
- 18:08Speaker 5: the appropriate it is for the pharmacy to be chosen,
- 18:13Speaker 5: and then obviously how specialty kind of complex it makes
- 18:17Speaker 5: it a little bit more complex.
- 18:19Speaker 7: Yeah, I think that the hard part here was getting
- 18:23Speaker 7: the Timely platform widely adopted so that you know, we're
- 18:26Speaker 7: doing about six million patient messages a week. Once you've
- 18:31Speaker 7: got that in place, it's more of an enhancement of
- 18:33Speaker 7: the existing functionality that patients are used to receiving.
- 18:36Speaker 10: They're used to getting the text from their doctor.
- 18:38Speaker 7: They can go in and they can see you know
- 18:41Speaker 7: copay information, cost information for specialty medications, that content is
- 18:45Speaker 7: just a little bit different, right, So it's really again
- 18:48Speaker 7: about keeping it within what patients are used to doing now,
- 18:52Speaker 7: but just being smart enough to know that this is
- 18:54Speaker 7: a specialty med is going to this pharmacy and there
- 18:56Speaker 7: are certain requirements, so there's a certain additional set of
- 19:00Speaker 7: information that we benefit the patient at that time.
- 19:02Speaker 10: So again it's.
- 19:07Speaker 7: If we have the intelligence to know what the doctor wrote,
- 19:10Speaker 7: why the patient's been prescribed that medication, where it's going,
- 19:13Speaker 7: and what the requirements for that specific medication and pharmacy are.
- 19:18Speaker 7: We have all the tools within our bag, so to speak,
- 19:22Speaker 7: to be able to address it. And then it's just
- 19:24Speaker 7: about making it easy for the patient and how much
- 19:26Speaker 7: of it can we do so that we're just giving
- 19:29Speaker 7: updates and nudge to the patient as opposed to saying, hey,
- 19:33Speaker 7: you know.
- 19:33Speaker 10: Your pa is stuck. You need to go call a
- 19:35Speaker 10: bunch of people.
- 19:36Speaker 7: You know, it's really about doing that on behalf of
- 19:39Speaker 7: the patient.
- 19:40Speaker 3: It can call.
- 19:41Speaker 5: When I think of on behalf of the patient, I immediately
- 19:44Speaker 5: think of our quarterback of the entire treatment program, which
- 19:47Speaker 5: is our physicians. And now the physician looks to the
- 19:50Speaker 5: EHR to say, is this patient, this is five days
- 19:57Speaker 5: after I prescribe this medication, have they start art the medication.
- 20:01Speaker 5: Number two scenario is, hey, it's been three months. Where's
- 20:05Speaker 5: this patient at with their therapy? All of a sudden,
- 20:08Speaker 5: we jettison nine months ahead. Hey are they adherent to
- 20:12Speaker 5: these medications? Jettison twelve months ahead? Hey, so listen timely
- 20:17Speaker 5: with the texting and the data, you're keeping track of
- 20:21Speaker 5: all of that.
- 20:22Speaker 4: One hundred percent of that. That's so valuable if I'm
- 20:25Speaker 4: that physician.
- 20:26Speaker 10: Yeah, there's kind of two sides to it, right.
- 20:28Speaker 7: It's one, try and get the initial prescription written, make
- 20:31Speaker 7: it in a way that it can be filled pretty
- 20:33Speaker 7: much immediately. To address your first point, you know, we
- 20:35Speaker 7: don't want it to be twenty one days until a
- 20:37Speaker 7: patient gets a specialty medication that they need. So once
- 20:41Speaker 7: you solve some of those upstream problems, you also smooth
- 20:44Speaker 7: out the entire downstream process.
- 20:46Speaker 3: So once they're on.
- 20:46Speaker 10: Therapy, exactly what you said, we know when their refills
- 20:50Speaker 10: are due.
- 20:50Speaker 7: We know that for certain therapies there's a big drop
- 20:53Speaker 7: off at thirty days or forty five days, or or
- 20:57Speaker 7: maybe not a drop off, but it's really valuable to
- 20:59Speaker 7: let them know that there's a certain side effect they
- 21:02Speaker 7: might experience and just keep them up to speed.
- 21:05Speaker 10: So once the therapy's written correctly, we help the doctor.
- 21:08Speaker 7: Then it really is about Okay, what are the right
- 21:10Speaker 7: touch points and through timely we have.
- 21:13Speaker 10: The mechanism to make those touch points.
- 21:14Speaker 7: So when we're working with the teams our customers, we
- 21:17Speaker 7: can get very specific and develop a campaign that it's
- 21:21Speaker 7: not you know, one size fits all for every patient
- 21:23Speaker 7: for every drug, but we want to make it personalized
- 21:26Speaker 7: to the patient, but then also specific to the therapy
- 21:29Speaker 7: that was prescribed.
- 21:31Speaker 5: So you've been in this industry, in this realm, this
- 21:35Speaker 5: technology and healthcare long enough to see where we were.
- 21:39Speaker 5: I remember when I started in pharmacy technology in two
- 21:43Speaker 5: thousand and four. My goodness, sqel server was a big deal.
- 21:49Speaker 5: I mean back the day there were zero SEQL systems
- 21:53Speaker 5: and long term care pharmacy we were the I was
- 21:56Speaker 5: representing one of the very first systems that was using.
- 21:59Speaker 5: So now all the sudden jettison ahead and I'm sitting
- 22:02Speaker 5: in twenty twenty five Access twenty twenty five here at
- 22:05Speaker 5: Assmbia Las Vegas is amazing, and now I start thinking
- 22:08Speaker 5: of what's on the edge, and I start thinking of
- 22:11Speaker 5: how is artificial intelligence going to impact my patient's care?
- 22:17Speaker 5: How is going how can we use AI to leverage
- 22:20Speaker 5: the patient's environment and their experience? And guess what Colin's
- 22:24Speaker 5: already given us in the other interview some of the reference,
- 22:28Speaker 5: but I want to hear it from you, Drew, because
- 22:30Speaker 5: you're that tech They're that techy, nerdy guy that can
- 22:33Speaker 5: actually give us some additional thought around that.
- 22:36Speaker 7: Yeah, I mean, I think it has applications kind of
- 22:40Speaker 7: in all the different checkpoints in the process. I think
- 22:43Speaker 7: the question is what is the most valuable place where
- 22:47Speaker 7: you can really let AI shine as opposed to make
- 22:50Speaker 7: inference for a provider or something like that. And so
- 22:53Speaker 7: for us, a lot of the opportunity is around consuming
- 22:57Speaker 7: a lot more information than what's in a DHR or
- 23:00Speaker 7: what we see from a patient and helping with that personalization.
- 23:04Speaker 7: So do we know if this kind of patient prefers
- 23:07Speaker 7: phone calls and they pick up after the second one,
- 23:09Speaker 7: or they need this kind of text message to be
- 23:11Speaker 7: able to get engaged. Like those are the things that
- 23:15Speaker 7: we're starting to get more sophisticated in. There's also automating
- 23:20Speaker 7: different parts of this specialty process. So there's robotic process
- 23:24Speaker 7: automation is now being used with different pay portals and
- 23:28Speaker 7: things for medically benefit covered drugs. And on the provider side,
- 23:32Speaker 7: they're sitting on top of this huge repository of clinical information.
- 23:36Speaker 7: But in a big way, it is just that it
- 23:38Speaker 7: is a repository of clinical information, right and it's not
- 23:41Speaker 7: always very usable. So when I think about AI, it's
- 23:45Speaker 7: really about how do we use it where it's not
- 23:48Speaker 7: going to be maybe flashy and sexy.
- 23:50Speaker 10: And doing cool things on the screen.
- 23:52Speaker 7: It's behind the scenes being a powerhorse and helping providers
- 23:55Speaker 7: and patients and streamlining a lot of the workflows and
- 23:58Speaker 7: the challenges that we talked about a second.
- 24:00Speaker 3: Go Drew.
- 24:01Speaker 5: What you're doing, though, is you're bending it back to
- 24:03Speaker 5: the patient and keeping the patient engaged. That's what Timely's
- 24:07Speaker 5: entire mission has been about, is engaging that patient. So
- 24:11Speaker 5: talk to us in the specially pharmacists that are listening
- 24:13Speaker 5: right now, talk to us about dialing into that patient's experience.
- 24:17Speaker 7: Yeah, for the patient in specialty therapies, it's a different
- 24:21Speaker 7: set of needs, you know, and so you need to
- 24:23Speaker 7: be able to support a lot of patients. What we
- 24:26Speaker 7: find is there are all kinds of support resources for
- 24:28Speaker 7: them around special team medications, but they don't know that
- 24:30Speaker 7: they exist. And so a big piece of it for
- 24:33Speaker 7: us is the output of the prescribing system should be
- 24:36Speaker 7: an engaged patient. It should be a script that's ready
- 24:39Speaker 7: to be filled and it should be going to the
- 24:40Speaker 7: right place, you know. And once you have an engaged patient,
- 24:44Speaker 7: there are different tactics and different support that that patient needs.
- 24:47Speaker 10: It could be they need to enroll.
- 24:49Speaker 7: In that pharmacy, they maybe need to confirm their address
- 24:52Speaker 7: if they are getting shipped to medication, or perhaps there's
- 24:56Speaker 7: financial savings and perhaps there's patient supporting women. So it's
- 25:01Speaker 7: really about, you know, based on the brand, based on
- 25:03Speaker 7: the payer, based on the specialty pharmacy, kind of turning
- 25:07Speaker 7: that into a very simple click click click experience for
- 25:10Speaker 7: the patient.
- 25:10Speaker 10: And get them, you know, get them to be.
- 25:13Speaker 7: Able to take that next step towards accessing your medication.
- 25:16Speaker 4: And that's just it. That's what they're used to.
- 25:19Speaker 5: I mean, the thing is bringing technology to a patient,
- 25:23Speaker 5: doing it in a way that they're already used to
- 25:25Speaker 5: using that tech and that interface their iPhone, they're droid, whatever,
- 25:30Speaker 5: it is Doctor First doesn't even ask you to download
- 25:33Speaker 5: the app. It's just right on the text. It's right
- 25:35Speaker 5: an SMS that makes absolute sense. It keeps it simple.
- 25:39Speaker 10: Yeah, exactly right.
- 25:41Speaker 7: I mean we we got pretty granular and looking at
- 25:43Speaker 7: different engagement rates and different and different strategies that are
- 25:48Speaker 7: out there today for specialty meds to engage patients. And
- 25:53Speaker 7: the one thing you just mentioned is always consistent. It's
- 25:56Speaker 7: you can't make it hard for the patient to access
- 25:59Speaker 7: just the initial set of information. So it's got to
- 26:01Speaker 7: be on the phone. It can't be an opt to download.
- 26:04Speaker 7: You don't have them create this big account, you know,
- 26:07Speaker 7: and then make the engagement very simple so that you
- 26:10Speaker 7: can then start to check off the boxes that are downstream.
- 26:13Speaker 7: If you don't have the top of that funnel wide enough,
- 26:16Speaker 7: with it being very very easy and intuitive and something
- 26:19Speaker 7: frankly they're already doing at scale, then it doesn't matter
- 26:22Speaker 7: how good your other systems are if the top of
- 26:27Speaker 7: that funnel is just too small.
- 26:28Speaker 5: I've seen the demo, I've seen the interaction with the
- 26:31Speaker 5: physician and the EHR system. I've seen the interaction the
- 26:34Speaker 5: interaction with the specialty pharmacist, and I've seen the interaction
- 26:38Speaker 5: with the patient in every single space. It keeps it
- 26:43Speaker 5: simple and that's so important right now with so much think,
- 26:47Speaker 5: so many things going on. Artificial intelligence sometimes confuses people,
- 26:51Speaker 5: whether they're thinking that is it something that I can't trust.
- 26:54Speaker 5: This is completely nullifying that because it's meeting patients, it's
- 26:58Speaker 5: meeting the physician and meeting the pharmacists where they already are.
- 27:02Speaker 7: That's exactly it. It's like a zero click experience for
- 27:05Speaker 7: all of them. You know, you know, nothing new to download,
- 27:08Speaker 7: nothing new to learn, nothing new to be trained on.
- 27:10Speaker 7: It's just fits within the existing clinical infrastructure and just works.
- 27:15Speaker 5: So absolutely a shout out to our specialty pharmacists out
- 27:19Speaker 5: there just to get a demo, I want you to
- 27:22Speaker 5: reach out to the doctor First team Doctor first dot com.
- 27:25Speaker 4: Easy enough to remember.
- 27:26Speaker 5: Also in the show notes, Collin's information through LinkedIn, Drew's
- 27:31Speaker 5: information through LinkedIn will be accessible.
- 27:34Speaker 4: Reach out to.
- 27:34Speaker 5: Both of them, connect with both of them, ask them questions,
- 27:38Speaker 5: schedule demos.
- 27:39Speaker 4: You will be blown away.
- 27:41Speaker 5: Especially by timely and the interaction between patients, physician, EHR,
- 27:47Speaker 5: pharmacy and execution and keeping people adherent. That's the most
- 27:51Speaker 5: important part of all of this for me, Drew, is
- 27:53Speaker 5: that we're serving the patient absolutely.
- 27:56Speaker 7: I mean, at the end of the day, everybody's a patient,
- 27:58Speaker 7: you know, and it makes it's what makes demoing timely
- 28:01Speaker 7: really easy. It's like you have a phone, Okay, you're
- 28:03Speaker 7: gonna get it, you know, So it's yeah. I'd encourage
- 28:06Speaker 7: anyone who's curious, you know, giving us, give us a
- 28:08Speaker 7: shout and we'll walk it through all right.
- 28:11Speaker 5: Here at Access to Pharmacy twenty twenty five, Assembia in
- 28:15Speaker 5: Vegas with Drew from Doctor First. Thank you so much
- 28:18Speaker 5: for being part of this, and thank you for your
- 28:20Speaker 5: support of the Pharmacy Podcast Network.
- 28:22Speaker 10: Thank you, Doug.
- 28:26Speaker 12: Hi there, my name's Fran Gregory. I'm the vice president
- 28:28Speaker 12: of Emerging Therapies at Cardinal Health. Emerging Therapies at Cardinal
- 28:32Speaker 12: Health is the selling gene therapy and biosimilar's team, and
- 28:35Speaker 12: you're listening to Pharmacy Podcast Network.
- 28:40Speaker 5: Fran, Welcome back to Access to Pharmacy twenty twenty five.
- 28:44Speaker 5: Last time we talked it was twenty twenty three, and
- 28:46Speaker 5: I said to you, I cannot believe how fast that went.
- 28:49Speaker 12: Time flies when you're having fun, doesn't it.
- 28:51Speaker 9: It does.
- 28:53Speaker 5: What we did talk about in twenty twenty three. Just
- 28:55Speaker 5: to the listeners if you don't know, if you google
- 28:57Speaker 5: Asembia twenty twenty three Pharma podcast Network, you'll find the
- 29:01Speaker 5: three part series where Fran was on. But we were
- 29:03Speaker 5: talking about biosimilars, and we were talking about the pharmacist
- 29:07Speaker 5: role in how biosimilars are positioned, how they're educating the providers,
- 29:11Speaker 5: how they're educating the patient, the family, the caregivers, about.
- 29:16Speaker 4: What does this mean for my loved one?
- 29:18Speaker 5: You know, what does this substance It sounds sometimes it's
- 29:21Speaker 5: probably the la person might even sound kind of scary,
- 29:24Speaker 5: But talk to us about the relationship of biosimilars where
- 29:28Speaker 5: Cardinal's been over the last two years, and then I
- 29:30Speaker 5: can't wait to talk to you about G.
- 29:31Speaker 9: And cell therapy.
- 29:32Speaker 10: Yeah.
- 29:33Speaker 12: Sure, biosimilars have come a long way, even in the
- 29:36Speaker 12: last couple of years since we talked. And if you
- 29:38Speaker 12: think about the biosimilar industry, in the biosimilar market, it
- 29:43Speaker 12: has officially been ten years since the first biosimilar has launched.
- 29:47Speaker 12: In fact, Cardinal Health published ten Years of Biosimilars or
- 29:50Speaker 12: a Decade of Biosimilars just a few weeks ago to
- 29:53Speaker 12: kind of highlight some of the successes that we've had
- 29:55Speaker 12: in that biosimilar space. So the role of the pharmacists
- 29:58Speaker 12: has become extra dainly critical in the biosimilar market, and
- 30:03Speaker 12: that is because we've kind of moved out of the
- 30:04Speaker 12: medical benefit biosimilars where the providers, the healthcare providers, physicians, nurses,
- 30:09Speaker 12: we're really working with those products very closely into the
- 30:12Speaker 12: pharmacy benefits. So pharmacists have the opportunity to counsel patients
- 30:16Speaker 12: on the value of these and the safety and the
- 30:18Speaker 12: efficacy as well of these biosimilar products and really encouraging
- 30:22Speaker 12: patients to give them a shot and to recognize as
- 30:26Speaker 12: healthcare savings that biosimilars promise.
- 30:29Speaker 5: So when I think of that and I hear pharmacists
- 30:33Speaker 5: that are specializing in something in maybe a blood disworder
- 30:36Speaker 5: or whatever, when is it time to educate the next
- 30:41Speaker 5: generation of pharmacists. How much of this is happening at
- 30:44Speaker 5: the pharmacy schools and education around biosimilars.
- 30:46Speaker 12: Do you think that's a great question. In fact, when
- 30:48Speaker 12: I graduated from pharmacy school, I'm not going to mention
- 30:51Speaker 12: the year and I hope nobody nobody figures that out.
- 30:53Speaker 12: But there was absolutely no mention of really biologics at all.
- 30:57Speaker 12: You know, we were really talking about small molecules, and
- 30:59Speaker 12: bio logics did exist, but there was not a lot
- 31:02Speaker 12: of education. And looking to today's pharmacy students, that is
- 31:07Speaker 12: a one point eighty. Thankfully, pharmacy schools have absolutely stepped
- 31:11Speaker 12: up to the plate as far as educating pharmacists on
- 31:13Speaker 12: not only you know, biosimilars biologics, but selling gene therapy
- 31:17Speaker 12: products as well, and even more broadly, educating pharmacists that
- 31:22Speaker 12: they have many, many career opportunities to specialize and help
- 31:25Speaker 12: patients in a number of different ways than you know
- 31:28Speaker 12: what was kind of taught when I was in pharmacy school.
- 31:30Speaker 5: If I were a pharmacist, I would be a little
- 31:33Speaker 5: bit more aggressive for my patient then a lot of
- 31:38Speaker 5: pharmacists that I run into because obviously I'm saying this,
- 31:41Speaker 5: I haven't been beat down like our pharmacists get beat
- 31:44Speaker 5: down in the processes. But when is it time to
- 31:47Speaker 5: reach out to the physician, reach out to the family
- 31:49Speaker 5: and the patient and say this is a perfect opportunity
- 31:53Speaker 5: for multiple reasons to go and using something that's a
- 31:57Speaker 5: biosimilar or gene cell therapy or something where it's that
- 32:00Speaker 5: pharmacists that's advocating for the best case, which includes costs sometimes.
- 32:05Speaker 5: So when is it talk to me about that ecosystem?
- 32:07Speaker 5: When is it time for our specialty pharmacists.
- 32:10Speaker 4: Is it to be a little bit more aggressive out there?
- 32:13Speaker 12: I would say now, I would say anytime is a
- 32:15Speaker 12: great time for a specialty pharmacist to be more aggressive
- 32:17Speaker 12: and more outspoken about how we can benefit patients. I
- 32:20Speaker 12: think that there's a huge opportunity again in the biosimilar space.
- 32:24Speaker 12: Humera the top selling drug in the world for years
- 32:27Speaker 12: on end, no longer so because of biologic or biosimilar
- 32:32Speaker 12: entry into the market, and pharmacists are one of the
- 32:35Speaker 12: main reasons why biosimilar at allumin mAbs have been so successful.
- 32:40Speaker 12: So I think, you know, when you think about biosimilars,
- 32:43Speaker 12: that's one thing, but selling gene therapies it's the complete
- 32:46Speaker 12: flip side. These are innovative products that can save patients' lives,
- 32:51Speaker 12: and sometimes physicians don't know about these treatments, but it
- 32:54Speaker 12: is a pharmacist's role to know and understand all of
- 32:57Speaker 12: the treatment options available for a patient and to really
- 32:59Speaker 12: be outspoken about what can benefit that patient with the
- 33:03Speaker 12: condition that they are experiencing.
- 33:06Speaker 5: Where is the expansion happening. Cardinal has an interesting position
- 33:10Speaker 5: because you get to see things from a wholesaler's perspective
- 33:15Speaker 5: drug development in the future of where things are going.
- 33:18Speaker 5: I'm sure you're in contact with FDA and some capacity,
- 33:21Speaker 5: so you really have some eyes on things from a
- 33:24Speaker 5: really interesting perspective.
- 33:25Speaker 4: So I want to know where's the growth coming from.
- 33:28Speaker 5: Talk to us about the expansion of specialty pharmacy and
- 33:31Speaker 5: our health systems.
- 33:32Speaker 12: The growth in specialty pharmacy is coming from all angles.
- 33:35Speaker 12: I think I've heard so many quotes here at ASSEMBIA
- 33:38Speaker 12: this week around how much specialty pharmacy is just taking off.
- 33:42Speaker 9: You know, small.
- 33:43Speaker 12: Molecule products are really kind of in the background at
- 33:46Speaker 12: this point, and specialty pharmacy is one hundred percent of
- 33:48Speaker 12: the focus. So if you think about where specialty pharmacy
- 33:52Speaker 12: is going, obviously I focus on selling gene therapies, which
- 33:55Speaker 12: are obviously the most high cost products in the healthcare
- 33:58Speaker 12: system today, arranging for five hundred thousand up to over
- 34:01Speaker 12: four million dollars per treatment regimen, So huge opportunity for
- 34:06Speaker 12: Cardinal Health to step in and partner with manufacturers healthcare
- 34:09Speaker 12: providers and payers to make sure that these products can
- 34:12Speaker 12: get to patients.
- 34:14Speaker 10: Wow.
- 34:14Speaker 5: All right, so when I think of health system, that
- 34:18Speaker 5: makes sense. Hospitals are building their own specialty pharmacies for
- 34:21Speaker 5: a lot of great reasons because that's where the patients
- 34:24Speaker 5: are and needing it. But let's talk about community pharmacies
- 34:28Speaker 5: I think of I'm using him as an example again
- 34:31Speaker 5: because he's one of my favorites.
- 34:32Speaker 4: He's also a friend.
- 34:33Speaker 5: But Chris Antipas out of Pittsburgh community pharmacy start, but
- 34:38Speaker 5: now he's running helping to run a specialty pharmacy which.
- 34:42Speaker 4: Is really Paragne Health.
- 34:43Speaker 5: So talk to me about the realm of the community pharmacy,
- 34:48Speaker 5: because Cardinal Health is rich in the support of our community.
- 34:51Speaker 12: Pharmacies, absolutely, and the community pharmacy is not lacking in
- 34:56Speaker 12: any way, shape or form the capability to work with
- 34:59Speaker 12: some of these very calm like specialty products. Unfortunately, in
- 35:04Speaker 12: the US healthcare system, community pharmacies are somewhat limited in
- 35:08Speaker 12: what they can actually participate in and be involved in
- 35:11Speaker 12: because of some of the payer PBM complexities that we face. However,
- 35:15Speaker 12: that's not to say that specialty pharmacies are outside of
- 35:19Speaker 12: that realm. In fact, we're seeing data coming from a
- 35:23Speaker 12: number of sources that are showing that small specialty pharmacies
- 35:27Speaker 12: are playing an increasingly more important role in managing some
- 35:31Speaker 12: of these extremely complex therapies limited distribution, exclusive distribution products.
- 35:37Speaker 12: And I think this is really a huge opportunity for
- 35:40Speaker 12: even small specialty pharmacies just starting out to really make
- 35:43Speaker 12: a big difference and you know, providing better clinical care
- 35:47Speaker 12: potentially than some of those larger, larger specialty pharmacies that
- 35:51Speaker 12: are really volume focused.
- 35:53Speaker 5: Fran Gregory Cardinal Health, focusing on the realm of the
- 35:57Speaker 5: advancement innovation in locations and gene and soul therapy, and
- 36:03Speaker 5: it's just exciting. And thank you so much for this
- 36:05Speaker 5: update here at Access to Pharmacy twenty twenty five. Thank
- 36:09Speaker 5: you so much, Matthew Lundy and Sabine Hasni from Walmart's
- 36:18Speaker 5: Specialty here at Access twenty five.
- 36:21Speaker 4: This is great to have you here, Sabine. It's good
- 36:23Speaker 4: to see you again.
- 36:24Speaker 11: Yes, likewise, good to see you again too, Todd.
- 36:26Speaker 5: Last time you were on the show, I think it
- 36:28Speaker 5: was NASP that's right, twenty it was twenty four, twenty
- 36:33Speaker 5: five happened, Yes, I can't let's check of everything, all right,
- 36:37Speaker 5: So your guest today and our guest which I haven't
- 36:40Speaker 5: met you yet, Matt, talk to me about your role
- 36:43Speaker 5: in specially pharmacy.
- 36:44Speaker 4: How'd you get into specially pharmacy specifically?
- 36:46Speaker 13: Yeah, So I've got a you know, twenty five year
- 36:49Speaker 13: his or career in healthcare, and it started as a
- 36:53Speaker 13: as a retail pharmacist in Walmart. And you know, you
- 36:57Speaker 13: know those communities that we serve at Walmart, those patients
- 37:00Speaker 13: are relying on those pharmacists, and so I got the
- 37:02Speaker 13: experience that firsthand.
- 37:04Speaker 3: And when we rolled out the Ford our.
- 37:05Speaker 13: Prescription program in two thousand and six, you could see
- 37:08Speaker 13: just the incredible value in that it brought to our
- 37:13Speaker 13: customers in the fact that they started using their medications
- 37:16Speaker 13: the right way. It's a powerful message, and it really
- 37:19Speaker 13: got me hooked on access and the importance of having
- 37:22Speaker 13: a pharmacist available to that, you know, to that customer.
- 37:25Speaker 13: And also Walmart's brand in the community. It's it's a
- 37:28Speaker 13: really strong brand. And and so I continue to move through
- 37:33Speaker 13: my career in different different operations roles and then get
- 37:35Speaker 13: into the pair relations space, which that's you know, PPM
- 37:39Speaker 13: negotiations and contracting as well as health plan you know, discussions, negotiations, contracting,
- 37:44Speaker 13: et cetera. And you know, just just I could see
- 37:48Speaker 13: that there were some opportunities for us to improve how
- 37:52Speaker 13: customers think about Walmart, and especially especially in the specialty area.
- 37:56Speaker 13: It's really a challenge. You know what you're when you're
- 37:59Speaker 13: diagnosed with a debilitating disease, it.
- 38:02Speaker 12: Is a.
- 38:04Speaker 9: It is a you know, it's a life changing event
- 38:06Speaker 9: for them.
- 38:07Speaker 13: And so to help navigate that that customer through that
- 38:12Speaker 13: through that life changing event is such an important part
- 38:14Speaker 13: of pharmacy. And as you think about the growth in
- 38:17Speaker 13: the in those in those in those areas, the growth
- 38:20Speaker 13: in the pipeline that is specialty, it's extremely important to
- 38:24Speaker 13: have someone help that.
- 38:27Speaker 4: Customer or patient through that journey.
- 38:29Speaker 13: And I can't think of a better company than Walmart
- 38:31Speaker 13: to do that that. Who trust us to do their
- 38:33Speaker 13: groceries every day, trust us with their you know, infant formula,
- 38:37Speaker 13: trust us with their prescriptions, trust us with their over
- 38:39Speaker 13: the counter medications. And so when I came back to Walmart,
- 38:43Speaker 13: I wanted to be in the specialty area. I wanted
- 38:45Speaker 13: to do business development, which is what I do. So
- 38:48Speaker 13: working with payer and trade to help tell that Walmart story.
- 38:53Speaker 5: Sabine, you and I have talked about this before, but
- 38:55Speaker 5: it's important and it's almost the sweet spot. The secret
- 38:58Speaker 5: sauce of Walmart's specialty is the fact that you're already
- 39:01Speaker 5: in the communities, you're trusted as this outlet of daily supplies,
- 39:07Speaker 5: Daily Living. Now we add in our pharmacist to it.
- 39:10Speaker 5: Pharmacists is the most trusted healthcare professional out there. I
- 39:14Speaker 5: love that stat And now we add in specialty, and
- 39:19Speaker 5: we think of trust and we think of access. Pharmacy
- 39:22Speaker 5: deserts is a big issue right now. Specialty, pharmacy and
- 39:26Speaker 5: Walmart combined has really mitigated and alleviate and kind of
- 39:32Speaker 5: pulled away the issues that deserts are causing. Kind of
- 39:35Speaker 5: talk to us about how Walmart is in a very
- 39:38Speaker 5: special position.
- 39:39Speaker 4: Yeah, I'd love to.
- 39:41Speaker 11: So you're absolutely right. Right now, more than ever, I
- 39:45Speaker 11: think pharmacy deserts, healthcare deserts are definitely an issue. We
- 39:50Speaker 11: all see it on the news. In the last few years,
- 39:53Speaker 11: more pharmacies have had to close down for a number
- 39:56Speaker 11: of reasons than ever before. Right That means that they're
- 40:00Speaker 11: more patients out of easy access to healthcare and Walmart's
- 40:05Speaker 11: presence in those areas right positions us to take care
- 40:10Speaker 11: of those patients. There's an opportunity for us to be
- 40:12Speaker 11: able to engage with patients and provide them access to
- 40:15Speaker 11: care that they otherwise would not have access to. Thinking
- 40:18Speaker 11: about specialty pharmacy and where that fits into the picture,
- 40:23Speaker 11: A great example of how Walmart has married those two
- 40:27Speaker 11: concepts is through our specialty at retail concept right through
- 40:32Speaker 11: our specialty pharmacies of the community. Essentially, what we've done
- 40:35Speaker 11: is for certain diseases where it makes sense, we've taken
- 40:39Speaker 11: the concept of providing specialty care outside of just that
- 40:43Speaker 11: centralized model out into the field. So when you think
- 40:47Speaker 11: of things like HIV or certain autoimmune conditions, where our
- 40:52Speaker 11: pharmacists are out there in the field, our teams are
- 40:55Speaker 11: out there with that extra level of clinical training, empathy,
- 40:58Speaker 11: cultural competence to be able to engage those patients, to
- 41:02Speaker 11: educate them, and to connect them to resources that are
- 41:06Speaker 11: intended to bring them to better health outcomes.
- 41:09Speaker 5: All Right, I want to kind of let our listeners
- 41:12Speaker 5: know how it works, because not every Walmart that has
- 41:16Speaker 5: a pharmacy in it is necessarily going to be a
- 41:20Speaker 5: specialty pharmacy in and of itself, but Walmart's specialty has
- 41:25Speaker 5: a system, has protocols, has like this workflow that you
- 41:29Speaker 5: can service any of your Walmart's pharmacies because you're almost
- 41:33Speaker 5: like in a central location or something.
- 41:35Speaker 4: Talk to our listeners about how that works.
- 41:38Speaker 13: Yeah, So, you know, part of our goal is to
- 41:41Speaker 13: create an extension in the community, as Simmins said, and
- 41:45Speaker 13: so our central facility in Orlando is able to support
- 41:48Speaker 13: the stores in any fashion.
- 41:49Speaker 4: So whether it's you know, whether it's.
- 41:52Speaker 13: Help with you know, figuring out the right access to
- 41:54Speaker 13: the right drug and where they need to go, or
- 41:56Speaker 13: actually shipping the drug to the store to have the
- 41:59Speaker 13: patient pick it up there and have our pharmacists help
- 42:01Speaker 13: council there. You know, this sort of central model with
- 42:05Speaker 13: extensions in the community is really important because of what
- 42:07Speaker 13: we just talked about from a from an access perspective,
- 42:10Speaker 13: and you know where that is. You know, we have
- 42:12Speaker 13: four thousand stores and underserved communities, and so having Walmart
- 42:16Speaker 13: as sort of the beacon of everything, including healthcare, is
- 42:19Speaker 13: a really important part of how we think about ourselves
- 42:23Speaker 13: as far as specialty pharmacy that we do have. As
- 42:27Speaker 13: being said, some specialized stores that are stores that specialize
- 42:31Speaker 13: in specific disease states, so things like HIV or autoimmune,
- 42:35Speaker 13: and in those stores, customers receive even a higher level
- 42:38Speaker 13: of care, specialized care really you know, the pharmacists have
- 42:42Speaker 13: been trained, educated, they're working closely with the position offices
- 42:45Speaker 13: to help that patient find the rights level of care
- 42:49Speaker 13: and the right access to their medications and just you know,
- 42:52Speaker 13: in some cases we're expanding. In an example in Colorado,
- 42:56Speaker 13: we're expanding into a test and prep scenario where we
- 43:01Speaker 13: will actually do the.
- 43:01Speaker 9: Test for an HIV patient.
- 43:03Speaker 13: We were able to build that test or build for
- 43:06Speaker 13: that test and then provide the prepism as they are negative.
- 43:08Speaker 13: And so things like that where the you know, the customer,
- 43:12Speaker 13: the patient doesn't have to go you know, to multiple
- 43:14Speaker 13: places and it just gets that access right away. It's
- 43:17Speaker 13: going to help, you know, help that disease state continue
- 43:20Speaker 13: to be you know, gives you that battle to end.
- 43:23Speaker 9: That disease essentially right.
- 43:24Speaker 13: And so we feel really good about where we in
- 43:27Speaker 13: those communities that we serve in those areas in Colorado
- 43:30Speaker 13: specifically that we have eight stores doing that or will
- 43:33Speaker 13: be doing that.
- 43:34Speaker 3: We're pretty excited about that.
- 43:35Speaker 5: Sabine I wanted to know. It is a follow up
- 43:38Speaker 5: to what Matthew just said. So you might have specialists
- 43:41Speaker 5: in one specific pharmacy that really hone in on let's
- 43:44Speaker 5: say HIV. However, there might be a blood disorder or
- 43:48Speaker 5: cancer or something else that someone else is going through.
- 43:51Speaker 5: The Specialty Pharmacy division of Walmart has the answers, they
- 43:54Speaker 5: have the protocols, the workflow rams reporting all the whole ecosystem.
- 43:59Speaker 4: However, in the.
- 44:02Speaker 5: First five days, the first thirty days, the first ninety days,
- 44:06Speaker 5: how is Walmart communicating with how busy the community pharmacies
- 44:10Speaker 5: can become, you know in that space, how do we
- 44:13Speaker 5: slow down some of that time that it's going to
- 44:15Speaker 5: be required to spend with those patients that are on
- 44:17Speaker 5: those medications.
- 44:19Speaker 4: Is Walmart doing that through telehealth?
- 44:21Speaker 5: Are you doing that through invitations to meet at a
- 44:24Speaker 5: specific Walmart like talk to us about the ongoing treatment
- 44:28Speaker 5: program and plan management.
- 44:30Speaker 4: Yeah.
- 44:30Speaker 11: So there are a couple of aspects to answer that question.
- 44:34Speaker 11: One is that if you have a patient who has
- 44:38Speaker 11: a prescription for something that is like an infusion drug
- 44:43Speaker 11: or on caolitic that can only be serviced out of
- 44:45Speaker 11: the central specialty pharmacy, we have essentially a seamless process
- 44:49Speaker 11: where our field, the entire field, not just certain stores,
- 44:53Speaker 11: can transfer that prescription electronically to the central specialty pharmacy
- 44:58Speaker 11: to reduce some of that turnar time. And that's when
- 45:01Speaker 11: the central specialty pharmacy teams to act on that right
- 45:04Speaker 11: within that business day to get that prescription turned around
- 45:07Speaker 11: as soon as possible for the patient. That's one aspect
- 45:10Speaker 11: of it. The other aspect of it is that you
- 45:12Speaker 11: are going to have, as I think your question implied,
- 45:16Speaker 11: is that you're going to have specialty medications that can
- 45:18Speaker 11: be filled within the field. Like Humora is a great
- 45:21Speaker 11: example of that, where pairs allow that patients are going
- 45:24Speaker 11: to be getting their humyra at the retail pharmacy in
- 45:27Speaker 11: those cases, to your point, right, freeing up that pharmacist
- 45:31Speaker 11: bandwidth to be able to speak to patients and to
- 45:33Speaker 11: be able to counsel them. Walmart has made an extensive
- 45:36Speaker 11: investment over the past several years to allow our pharmacy
- 45:40Speaker 11: teams to form those relationships in a meaningful way. Things
- 45:45Speaker 11: like you know, our central fills right, allowing technicians to
- 45:49Speaker 11: practice at the top of their license, all those types
- 45:53Speaker 11: of things, right, Pharmacy delivery all these things have come
- 45:56Speaker 11: together to give our pharmacists the band to do what
- 46:01Speaker 11: they love most and what they are experts at, which
- 46:03Speaker 11: is providing excellent pharmaceutical care. So that is how then they,
- 46:08Speaker 11: for those patients who are getting serviced out of the pharmacy,
- 46:11Speaker 11: can do that extra level of counseling and all those
- 46:14Speaker 11: other things, whether or not their spock.
- 46:16Speaker 4: That's great, Matthew.
- 46:18Speaker 5: Why is it important to be a part of this
- 46:20Speaker 5: the ASSEMBIA annual get together?
- 46:22Speaker 4: Why do you invent?
- 46:23Speaker 5: Why does Walmart specially invest to be part of Access
- 46:26Speaker 5: to Pharmacy twenty twenty five And that's.
- 46:28Speaker 13: A great question, Todd. So we feel like this is
- 46:31Speaker 13: an event that allows us to have these really meaningful discussions,
- 46:36Speaker 13: whether they're with manufacturers or vendors that service specialty pharmacies,
- 46:41Speaker 13: and a lot of these conversations manifest into some incredible
- 46:45Speaker 13: opportunities to serve our customers better. And so when you
- 46:49Speaker 13: get together and you're talking about ways to improve outcomes,
- 46:54Speaker 13: improve the care that our patients receive, we identify new product,
- 47:00Speaker 13: new paths, new new things to do in the community
- 47:03Speaker 13: that we serve, and so these conversations are priceless.
- 47:06Speaker 9: Really, it's an.
- 47:08Speaker 13: Incredible opportunity to get together with just a great, you know,
- 47:12Speaker 13: like minded group of healthcare.
- 47:14Speaker 5: Professionals, Sabine and Matthew. It's been just a pleasure to
- 47:18Speaker 5: talk with you. Getting updates now from Walmart specially, it's
- 47:21Speaker 5: becoming a tradition. So now you're going to have to
- 47:23Speaker 5: make sure that we meet back up at SEMBA twenty
- 47:26Speaker 5: twenty six. But I'll probably be seeing you at ANSP.
- 47:28Speaker 4: Twenty twenty five.
- 47:29Speaker 12: Two.
- 47:30Speaker 4: Yes, absolutely, thank you for being here.
- 47:32Speaker 11: Yeah, thank you, tom Us.
- 47:37Speaker 8: We hope you're enjoying this episode of the ASX twenty
- 47:39Speaker 8: five Access to Pharmacy post show. We're back with some
- 47:42Speaker 8: pharmacy trivia. What trees bark is used to create aspirin? Okay,
- 47:49Speaker 8: are you ready to see if you got it? If
- 47:50Speaker 8: you said willow bark, you got it. Willow trees always
- 47:53Speaker 8: make me think of Harry Potter. I wonder if wizards
- 47:56Speaker 8: and Witches got that one figured out too.
- 48:00Speaker 5: Pharmaceutical Strategies Group here with Morgan Lee AXS twenty five
- 48:05Speaker 5: Access to Pharmacy in Vegas.
- 48:08Speaker 4: Morgan, welcome to the show.
- 48:09Speaker 10: Hi, thanks so much for having me.
- 48:11Speaker 5: All right, you know what irritates me? We have some
- 48:14Speaker 5: amazing groups of people, people like Pharmaceutical Strategy Group, who's
- 48:20Speaker 5: doing amazing research. You're developing white papers, you're developing studies,
- 48:25Speaker 5: and sometimes, in this case, our specially pharmacists and people
- 48:28Speaker 5: who are running specially pharmacies don't get a chance to
- 48:31Speaker 5: really dig into that research. Something has just come out
- 48:34Speaker 5: that we want to get a lot more attention to
- 48:36Speaker 5: for our listeners. Morgan tell us about this new research
- 48:39Speaker 5: project that you're working on.
- 48:41Speaker 14: Happy to well, and we're really excited to be here
- 48:44Speaker 14: at Asymbia to kick off our report season. Our report
- 48:47Speaker 14: season includes four annual market research reports. Trends and Specialty
- 48:51Speaker 14: Drug Benefits is our first report of the report season,
- 48:55Speaker 14: and in this report, we surveyed a little over two
- 48:57Speaker 14: hundred and thirty payers on a y variety of specialty
- 49:01Speaker 14: drug benefit design and management topics. I'll tell you we've
- 49:04Speaker 14: been conducting this research for over a decade and it's
- 49:08Speaker 14: really interesting to track trends over time. So for example,
- 49:11Speaker 14: this year, we found year over year a nearly ten
- 49:14Speaker 14: percent increase in the percentage of payers who selected managing
- 49:18Speaker 14: specialty trend or managing total cost of care as their
- 49:21Speaker 14: very top goal for specialty drug management. As another example,
- 49:25Speaker 14: we found an increase in the percentage of payers who
- 49:27Speaker 14: are carving out some utilization management services from their PBM
- 49:32Speaker 14: to other vendors. And then I'll also just say that
- 49:35Speaker 14: this report also gives us the opportunity to add new
- 49:38Speaker 14: questions on topics of interest. So for example, this year
- 49:41Speaker 14: we added questions on rebates for drugs that are covered
- 49:44Speaker 14: under the medical benefit and additional questions on cancer screening
- 49:48Speaker 14: and treatment. And then finally I'll just say that this report,
- 49:52Speaker 14: like all of our market research reports, is available for free,
- 49:55Speaker 14: and I really encourage listeners to explore the report for
- 49:58Speaker 14: insights on a wide variety of top fix everything from
- 50:01Speaker 14: selling gene therapies to tracking capabilities and challenges in this space.
- 50:06Speaker 14: So I've noted a few things, and we have Renee,
- 50:08Speaker 14: who is I believe one of your top fifty most
- 50:11Speaker 14: influential in pharmacy. Is another person from PSD who I
- 50:15Speaker 14: work with closely, and I'd love to hear a little
- 50:17Speaker 14: bit of what she has to say as well.
- 50:19Speaker 5: Absolutely, Renee is one of the most influential people in
- 50:22Speaker 5: our profession. Voted to voted on by her peers for
- 50:26Speaker 5: the twenty twenty four season. And with that, I'd like
- 50:29Speaker 5: to welcome Renee and once again congratulate you for your
- 50:33Speaker 5: positioning and your influence and our profession. And it's nice
- 50:37Speaker 5: to see you and it's nice to have you back
- 50:38Speaker 5: on the show.
- 50:39Speaker 10: Thanks Todd.
- 50:40Speaker 15: So with this report, I always find it interesting for
- 50:44Speaker 15: what the pairs are talking about, and when I say pairs,
- 50:46Speaker 15: it includes both health plans and employers and what they
- 50:50Speaker 15: indicate as their top goals.
- 50:52Speaker 4: So in addition to what.
- 50:54Speaker 15: Morgan mentioned, what was came closely in was what ranked
- 51:01Speaker 15: kind of third behind affordability, because that's still a priority,
- 51:04Speaker 15: but reducing inappropriate utilization came in third.
- 51:07Speaker 4: So over half the.
- 51:08Speaker 15: Respondents actually listed as second or third as a priority.
- 51:13Speaker 4: And utilization matters.
- 51:14Speaker 15: So even yesterday in one of the talks, they were
- 51:17Speaker 15: talking about the drug sales for twenty twenty four and
- 51:20Speaker 15: they said seventy eight percent of the drug sells where volume.
- 51:24Speaker 10: Was the responsible party for it.
- 51:26Speaker 15: And so when you don't think about managing utilization, I
- 51:29Speaker 15: think you're not going to be optimal at managing your
- 51:31Speaker 15: drug spends. So we always talk about, you know, it
- 51:33Speaker 15: doesn't matter how expensive a drug is if no one's
- 51:35Speaker 15: using it, right, so you can't just consider cost, you
- 51:38Speaker 15: have to consider how many people are using it, and
- 51:40Speaker 15: so we always say you must manage both costs and utilization.
- 51:44Speaker 15: Another interesting topic in the survey, so I really encourage
- 51:47Speaker 15: people to go out and read. The report is looking
- 51:49Speaker 15: at are there alternatives to you know, are people seeking
- 51:52Speaker 15: alternatives to the rebate driven approach or alternatives to you know,
- 51:57Speaker 15: the traditional PBM model. So there's questions around that, and
- 52:00Speaker 15: we're seeing more interest in payers and you know, trying
- 52:03Speaker 15: to align their PBM solutions to better fit their needs,
- 52:07Speaker 15: so customize it more to you know, what their challenges are.
- 52:11Speaker 15: I think the days of the one size fits all
- 52:13Speaker 15: model are kind of you know, gone away. And then lastly,
- 52:16Speaker 15: I would say we have some questions that are looking
- 52:18Speaker 15: at you know, what's really challenging payers from a trend
- 52:21Speaker 15: perspective in specialty, so a lot about a little bit
- 52:24Speaker 15: about biosimilars and seal gene therapies.
- 52:26Speaker 4: We've had changes in the.
- 52:27Speaker 15: Industry related to both of those kind of not what
- 52:31Speaker 15: the industry expected. So it's kind of neat to see,
- 52:35Speaker 15: you know, how the payers are looking at that and
- 52:37Speaker 15: what their responses are to our questions. So thank you
- 52:39Speaker 15: for you know, the time to kind of tout our report,
- 52:42Speaker 15: so we are very excited about it and hope that
- 52:45Speaker 15: some of your listeners will find the information useful.
- 52:49Speaker 5: Absolutely in this episode in the show notes, you will
- 52:52Speaker 5: have a link in order to.
- 52:54Speaker 4: Get access to this report.
- 52:56Speaker 5: But for our listener's sake, where should they go to
- 53:00Speaker 5: to run into this information.
- 53:02Speaker 15: So the PhD website you could go out so it's
- 53:05Speaker 15: Pharmaceutical Strategies Group and go out to our website and
- 53:09Speaker 15: you'll be able to download the.
- 53:10Speaker 4: Report from there. There will be four this year.
- 53:12Speaker 15: This is the first one, so we're excited in our
- 53:14Speaker 15: report season is off to raging start.
- 53:17Speaker 4: Excellent Renee, thank you so much.
- 53:20Speaker 5: We will be following up with you to get more
- 53:22Speaker 5: information to our Pharmacy Podcast Network listeners about these reports
- 53:27Speaker 5: and reach out to Ray She's on LinkedIn too.
- 53:29Speaker 10: Thanks todds.
- 53:35Speaker 16: Oh, I'm excited to be a guest host here for
- 53:37Speaker 16: Todd at the Pharmacy Podcast, number one podcast in the industry.
- 53:41Speaker 4: And this is Richard Brooke speaking today.
- 53:43Speaker 16: I've known Todd for several years through NASP and Todd
- 53:47Speaker 16: knows that I've oftentimes talk about generating data for pharmaceutical use.
- 53:52Speaker 16: I have a special guest here today, Keith Kalen is
- 53:55Speaker 16: from Nested Knowledge, who's going to talk about ways that
- 53:58Speaker 16: we find data. Keith, could you tell us a little
- 54:01Speaker 16: bit about your next knowledge platform.
- 54:03Speaker 9: Absolutely.
- 54:04Speaker 6: First of all, thank you Todd, Thank you Rich. Really
- 54:06Speaker 6: excited to be on the podcast. Nested Knowledge is an
- 54:09Speaker 6: evidence synthesis platform.
- 54:11Speaker 9: And what I mean by that is we can take published.
- 54:14Speaker 6: Evidence, unpublished evidence, any sort of literature, clinical trial, doctov records,
- 54:20Speaker 6: conference abstracts, internal data, and amalgamate them into a comprehensible
- 54:26Speaker 6: analytical framework which.
- 54:28Speaker 9: You can then glean insights out of.
- 54:29Speaker 6: So if you want to know comparative clinical effectiveness for
- 54:33Speaker 6: drugs devices, if you want to know epidemiological burden of illness,
- 54:38Speaker 6: if you want to know you know what the humanistic
- 54:40Speaker 6: burden is. That information exists out there. The challenges how
- 54:44Speaker 6: do you find it, how do you synthesize it, how
- 54:46Speaker 6: do you summarize it, and how do you analyze it.
- 54:49Speaker 16: So organizations like a smbio where we're at today and
- 54:53Speaker 16: NASP and AMCP do great jobs and bringing information that's
- 54:57Speaker 16: in the research realm to life. And I think Nested
- 55:01Speaker 16: Knowledge I've seen the benefit of identifying that research, where
- 55:04Speaker 16: it comes from, how it can be synthesized, How do
- 55:08Speaker 16: you take the data in extract the pearls.
- 55:12Speaker 6: That's a great question. Human in the loop AI. So
- 55:16Speaker 6: you have a process oriented sort of scientific best practice
- 55:21Speaker 6: where you go to a database, be it PubMed or
- 55:24Speaker 6: clinical traustica, or really wherever this evidence exists. You identify
- 55:28Speaker 6: relevant records, You build a taxonomy of concepts that will
- 55:32Speaker 6: then go in and abstract the granular data elements or
- 55:35Speaker 6: study elements that allow you to find the exact answer
- 55:39Speaker 6: you're looking for. So, if you are curious about a
- 55:44Speaker 6: patient subpopulation and the types of drugs that perform best
- 55:47Speaker 6: in that subpopulation, you're going to generate a brilliant strength
- 55:51Speaker 6: that's going to include those subpopulations in the therapies, and
- 55:53Speaker 6: then you're going to have an AI go out and
- 55:56Speaker 6: abstract the data points or the tech segments that help
- 55:58Speaker 6: you answer that question. There's a pre existing review, maybe
- 56:02Speaker 6: it's going to be a bunch of combined RCTs, and
- 56:05Speaker 6: then ultimately what you with the gold standard here is
- 56:08Speaker 6: a meta analysis, and traditionally that'll take you nine months
- 56:12Speaker 6: and a biostatistician, we actually have a no code meta
- 56:14Speaker 6: analysis function where you can get comparative clinical efficacy data
- 56:17Speaker 6: from different RCTs in a very short order.
- 56:21Speaker 16: And for those of you who haven't seen the platform,
- 56:24Speaker 16: we're going to work with Todd to see if we
- 56:25Speaker 16: could put a link in there so that people can
- 56:27Speaker 16: actually view it. I know that the Nested Knowledge platform
- 56:31Speaker 16: does a great job at generating text based or pictures
- 56:36Speaker 16: of the text of how it all forms in the ecosystem,
- 56:39Speaker 16: the taxonomy.
- 56:40Speaker 3: Can you explain a little bit about that?
- 56:42Speaker 9: Absolutely, it's a great question.
- 56:43Speaker 6: We're all about provenance, so I'm sure everyone listening to
- 56:48Speaker 6: this has used chat, GPT or another LLM. I'm a
- 56:51Speaker 6: huge fan of those tools. They absolutely have their place.
- 56:54Speaker 6: But if someone is going to make clinical decisions, if
- 56:58Speaker 6: someone is going to make reiinforsement decisions, if someone is
- 57:00Speaker 6: going to make something decid that can impact patient care,
- 57:05Speaker 6: provenance has to be a part of that conversation.
- 57:08Speaker 9: Where did that evidence come from?
- 57:09Speaker 6: Who found that evidence, what are the biases associated with
- 57:12Speaker 6: that evidence? Was it funded by industry, was it funded
- 57:14Speaker 6: by NIH when was it published?
- 57:16Speaker 9: What were the comorbidities of those underlying patients? So humans
- 57:20Speaker 9: in the loop.
- 57:21Speaker 6: AI abstraction with direct text linkage to the underlying studies
- 57:28Speaker 6: for where that came from. And most importantly, it's dynamic.
- 57:31Speaker 6: So every single piece of evidence that you interact with
- 57:35Speaker 6: on a daily basis, whether it's a systematic review published
- 57:39Speaker 6: in a journal or a guideline that is just a snapshot.
- 57:44Speaker 6: The ultimate vision is make it dynamic, have new evidence
- 57:47Speaker 6: ingested automatically as it comes out.
- 57:49Speaker 16: And if I recall a platform from when I've worked
- 57:51Speaker 16: with it, it's not just taking the abstract and summarizing
- 57:54Speaker 16: the abstract. It's actually delving into the manuscripts, pulling out
- 57:57Speaker 16: or the clinical trial document and saying, you know, we
- 58:01Speaker 16: show this is the temperature change that the patient saw.
- 58:04Speaker 16: Might not have been the pearl that was brought out
- 58:06Speaker 16: in the abstract, but it's some of that knowledge that
- 58:08Speaker 16: nested knowledge helps extract.
- 58:09Speaker 9: That's exactly right.
- 58:10Speaker 6: You can skim over the surface with abstracts like you said,
- 58:13Speaker 6: or you can go all the way down to that
- 58:15Speaker 6: one granular table in the manuscript that has that little
- 58:19Speaker 6: pearl that you're looking for. And most importantly, you take
- 58:21Speaker 6: all those pearls that came from all those individual tables
- 58:23Speaker 6: and you can combine them and do a no code
- 58:26Speaker 6: met analysis, which again that's the gold standard, that's what
- 58:28Speaker 6: people are usually driving at, but oftentimes it falls short
- 58:31Speaker 6: because of resourcing and technology.
- 58:32Speaker 9: So our vision is really to change that well.
- 58:34Speaker 16: And you know, I think about the Pharmacy podcast as
- 58:36Speaker 16: being a technology for getting information out there to the
- 58:39Speaker 16: peoples of the listeners. This is a way of taking
- 58:42Speaker 16: piece at does the platform do anything with audio files
- 58:45Speaker 16: or no audio yet?
- 58:47Speaker 6: Actually a lot of visualizations, a lot of visualizations, so
- 58:50Speaker 6: forest plots, super rankings, funnel plots for heterogeneity, I squared
- 58:55Speaker 6: itcs dashboards, maps.
- 58:57Speaker 9: No audio. That would be cool though, if you could.
- 59:00Speaker 6: Have an audio repository and an ai go and tag those.
- 59:03Speaker 16: I think one of the first times I saw the
- 59:05Speaker 16: platform in action, we were sitting and Keith was doing
- 59:08Speaker 16: a demo and it might have been one of his
- 59:10Speaker 16: partners at the time, but people were looking at the
- 59:13Speaker 16: plots that were coming out of that and saying, wow,
- 59:15Speaker 16: this looks like a poster that I would see presented here.
- 59:18Speaker 16: It's really almost publication grade graphics.
- 59:21Speaker 9: It is publication grade. We have Journals of Radiology, which
- 59:24Speaker 9: is a super.
- 59:24Speaker 6: High impact journal with a lot of readership, really high
- 59:27Speaker 6: quality evidence. They've published living systematic reviews and meta analyses
- 59:31Speaker 6: with embedded interactive visuals.
- 59:32Speaker 9: It is publication grade.
- 59:34Speaker 6: If you want to do an abstract, there's actually a
- 59:35Speaker 6: QR code you can link to a digital twin of
- 59:37Speaker 6: that abstract that helps helps the reader interpret what is
- 59:42Speaker 6: going on there, what's the underlying evidence, what was the methodology.
- 59:44Speaker 6: So absolutely, I think with there's a place for physical journals,
- 59:49Speaker 6: there's a place for physical abstracts. But if you're going
- 59:51Speaker 6: to do that, have a digital twin, have the link
- 59:53Speaker 6: and the linkage all the way through to the underlying data.
- 59:56Speaker 16: So one of the things I think about the nested
- 59:58Speaker 16: Knowledge platform is also that it's not limited to the US.
- 1:00:02Speaker 16: You can actually synthesize data from around the world. Hone
- 1:00:06Speaker 16: in on the different countries of interest. Are other countries
- 1:00:10Speaker 16: and organizations adopting the platform for their technology.
- 1:00:14Speaker 6: Believe it or not, we have more users in Europe
- 1:00:17Speaker 6: than we do in the United States. Europe is on
- 1:00:19Speaker 6: the cutting edge of comparative clinical efficacy and HTA research.
- 1:00:24Speaker 9: We have a lot of users in India.
- 1:00:25Speaker 6: And I mean, like you said, evidence is global, right
- 1:00:29Speaker 6: the shirt different subpopulations get sick at different rates. And
- 1:00:34Speaker 6: present differently depending on what part of the world they're in.
- 1:00:36Speaker 6: But ultimately, we're all people and we all get sick
- 1:00:39Speaker 6: in a very similar way. So if you can generate
- 1:00:41Speaker 6: evidence and synthesize evidence of the global context, you're going
- 1:00:44Speaker 6: to have a higher powered study, You're going to have
- 1:00:46Speaker 6: a better study ultimately than if you are geographically limited.
- 1:00:50Speaker 9: Now, it's a very important distinction to make.
- 1:00:52Speaker 6: Sometimes if you're doing a geography specific submission or analysis,
- 1:00:56Speaker 6: you want to be able to narrow in on the
- 1:00:58Speaker 6: evidence from that specific geography. But I think it's better
- 1:01:00Speaker 6: to have a database tagged according to the location of
- 1:01:03Speaker 6: where this evidence is coming from in the around the
- 1:01:05Speaker 6: globe than it is to just have, you know, North
- 1:01:08Speaker 6: American data.
- 1:01:09Speaker 16: So I believe I have this right, but I want
- 1:01:11Speaker 16: to make sure I get it right for the listeners.
- 1:01:13Speaker 16: If I'm looking at, say an anti bacterial product, and
- 1:01:16Speaker 16: I'm looking at the major pathogens in play in the US,
- 1:01:21Speaker 16: they might be very different than other parts of the world,
- 1:01:24Speaker 16: and the nets the knowledge platform can extract which pathogens
- 1:01:28Speaker 16: are showing up and which studies and which parts.
- 1:01:30Speaker 3: Of the world, and drugs being developed as well.
- 1:01:32Speaker 9: Absolutely we can.
- 1:01:33Speaker 6: We'll pick up the population that's getting sick, the interventions
- 1:01:36Speaker 6: that are treating them, the outcomes of interest from that
- 1:01:40Speaker 6: underlying data set, and then we'll automatically tag where these
- 1:01:43Speaker 6: studies are coming out from from a geographic location. So
- 1:01:45Speaker 6: you're exactly right that is that is automated, but you
- 1:01:50Speaker 6: can also as a human going and quality control that
- 1:01:52Speaker 6: and really understand where that evidence is bubbling up from.
- 1:01:55Speaker 16: So I'm seeing a lot of presentations around ASSEMBIA this
- 1:01:58Speaker 16: year on sale.
- 1:01:59Speaker 9: And gene therapies.
- 1:02:01Speaker 16: Would the nested knowledge be able to help me find
- 1:02:04Speaker 16: those types of publications?
- 1:02:05Speaker 9: Absolutely?
- 1:02:06Speaker 6: I think for something as cutting edges salagen therapy, I
- 1:02:08Speaker 6: would go not to the published literature, I would go.
- 1:02:11Speaker 9: To clinical trials dot gov.
- 1:02:12Speaker 6: And clinical trials dot gov is a gold mine of
- 1:02:16Speaker 6: high quality information, but the interface, with all to respect
- 1:02:19Speaker 6: the great people at clinical trials dot gov could.
- 1:02:21Speaker 4: Use a lot of work.
- 1:02:21Speaker 6: So instead of trying to improve their interface, what we
- 1:02:24Speaker 6: did is we actually built an API plug in with
- 1:02:27Speaker 6: clinical trials dot gov and we'll actually automatically abstract all
- 1:02:29Speaker 6: the relevant information from clinical trialsduck gov and put in
- 1:02:31Speaker 6: a structured format for our users to review. So if
- 1:02:35Speaker 6: you want to know what's coming out in salagen therapy.
- 1:02:37Speaker 6: I would encourage you to use our API with ct
- 1:02:40Speaker 6: dot gov and then build a visual mapping of all.
- 1:02:42Speaker 9: The upcoming therapies and their applications.
- 1:02:43Speaker 16: And you said, there's humans in the loop, so you know,
- 1:02:46Speaker 16: if I'm going do my application, I get stuck. Am
- 1:02:48Speaker 16: I getting a robocall about it? Or are you helping
- 1:02:51Speaker 16: me avoid that robo call?
- 1:02:54Speaker 6: We will walk you through every step of the tool.
- 1:02:56Speaker 6: We have humans on call to help our researchers. We
- 1:02:59Speaker 6: also do you have AIS to help as well? You know,
- 1:03:02Speaker 6: best of both worlds. We have human pre recorded videos,
- 1:03:06Speaker 6: human support calls, and then AIS to answer basic questions
- 1:03:09Speaker 6: about research structure or functionality as well.
- 1:03:11Speaker 16: While you guys are really taking the research world and
- 1:03:14Speaker 16: literature search world by storm here and I've seen the
- 1:03:18Speaker 16: growth over the past few years. How long has nested
- 1:03:20Speaker 16: knowledge been in existence? And what can you say about that?
- 1:03:24Speaker 6: So Carl, my technical co founder and CTO, he started
- 1:03:27Speaker 6: writing the code for this program over six years ago.
- 1:03:30Speaker 9: Now there was a lot of building that had to
- 1:03:32Speaker 9: happen first.
- 1:03:32Speaker 6: You can't just come out with a product a month
- 1:03:35Speaker 6: later that people are going to use. So I would
- 1:03:38Speaker 6: say We've been commercial for about four years, and I
- 1:03:40Speaker 6: would say past two years we've really seen a lot
- 1:03:43Speaker 6: of adoption by researches of all stripes, you know, and
- 1:03:47Speaker 6: for the pharmacy world out there, I would say you've
- 1:03:51Speaker 6: probably interfaced with some of the evidence that was generated
- 1:03:53Speaker 6: in the nested platform without even realizing us. For instance,
- 1:03:56Speaker 6: if you read an ICER assessment and you go to
- 1:03:59Speaker 6: their methods, they will they will note that they're using
- 1:04:01Speaker 6: nested knowledge for article selection. We're often in the background,
- 1:04:06Speaker 6: but I'm super happy with that. If we can make
- 1:04:09Speaker 6: evidence dissemination easier, better, faster, and more digestible, then I'm
- 1:04:13Speaker 6: all about that.
- 1:04:14Speaker 9: I don't need credit.
- 1:04:15Speaker 16: I'm just tickled pink that Todd allowed us to come
- 1:04:18Speaker 16: and guest host for his show tonight. One of the
- 1:04:21Speaker 16: questions I'm curious about is I've seen an increased presence
- 1:04:25Speaker 16: of nested knowledge on the podium at different meetings at
- 1:04:27Speaker 16: a MCP and I hear you have some upcoming places
- 1:04:31Speaker 16: where people can see the demo live at a meeting
- 1:04:34Speaker 16: as well as on the website.
- 1:04:35Speaker 9: We actually have two presentations at espor.
- 1:04:38Speaker 6: Rnita, who is our scientific director, is actually co presenting
- 1:04:41Speaker 6: the chief scientific officer of ISPOR. Doctor Mitchigashi Kevin, my
- 1:04:46Speaker 6: brother and co founder, is also presenting on basically the
- 1:04:49Speaker 6: effectiveness of AI for generating ghouli in queries when going
- 1:04:52Speaker 6: to pubman. So if you're at esport, I would encourage
- 1:04:54Speaker 6: you to go and watch one or both of those. Yeah,
- 1:04:58Speaker 6: I would actually like to shout out and thank Harry
- 1:05:01Speaker 6: Travis forgetting me that podium at AMCP. I had no
- 1:05:05Speaker 6: idea that there's this whole other side to comparative clinical
- 1:05:08Speaker 6: advocacy research outside of Farmer right, there's this whole world
- 1:05:10Speaker 6: of like PNT and Formulae who are really doing the
- 1:05:14Speaker 6: complement of the work.
- 1:05:15Speaker 9: That the manufacturers and the consultants do.
- 1:05:17Speaker 6: Right, it's all about what drugs work best for which patients,
- 1:05:22Speaker 6: and I think we're all just in the business of
- 1:05:24Speaker 6: trying to make sure that the right drugs get to
- 1:05:26Speaker 6: the right patients with at the right time, in the
- 1:05:28Speaker 6: right combination, and technology can really help us do that.
- 1:05:31Speaker 6: So we're providing evidence and finding evidence to help developers, manufacturers,
- 1:05:37Speaker 6: marketers look better with what's out there and giving them
- 1:05:41Speaker 6: a solid foundation to build upon.
- 1:05:43Speaker 3: Exactly.
- 1:05:43Speaker 9: Yeah, I couldn't put it beut of myself. Sounds great.
- 1:05:46Speaker 16: I look forward to learning more and more as I
- 1:05:49Speaker 16: work with the platform and listen to the podcast.
- 1:05:53Speaker 9: Thank you, thank you Rich, thank you Ton.
- 1:06:00Speaker 4: Friend Matt Gilbert here with me.
- 1:06:01Speaker 5: It seems like every time we meet we have microphones
- 1:06:04Speaker 5: in front of us and we're on a podcast.
- 1:06:06Speaker 17: I think we should get some good travel discounts. With
- 1:06:09Speaker 17: all the travel and we do. You should start riding together.
- 1:06:11Speaker 17: It's time for a private plane. I'll pick you up
- 1:06:13Speaker 17: in Pittsburgh.
- 1:06:15Speaker 9: That's awesome.
- 1:06:16Speaker 5: So we are at Assembia all Things Specialty. I say,
- 1:06:21Speaker 5: this is the super Bowl event of a specialty pharmacy business.
- 1:06:25Speaker 5: In your teams here the booth looks great, but let's
- 1:06:31Speaker 5: talk about that. Well, why specialty? What is special about
- 1:06:35Speaker 5: specialty when it comes from our safe positioning in itw Yeah.
- 1:06:41Speaker 17: I think the big thing for us is it all
- 1:06:43Speaker 17: revolves around adherence and keeping patients healthy and that trickles
- 1:06:48Speaker 17: back to manufacturers.
- 1:06:50Speaker 10: That benefits the patient.
- 1:06:51Speaker 17: The pharmacy, we really want to have patients stick adherent
- 1:06:55Speaker 17: and through our adherence packaging, both on the blister cardful
- 1:06:59Speaker 17: fit and the pouch packaging side. That's our main mission
- 1:07:03Speaker 17: is keeping a patient adherent and that flows really well
- 1:07:06Speaker 17: with a sembius mission.
- 1:07:07Speaker 5: So something that's special that happened with rx safe is
- 1:07:11Speaker 5: the acquisition through ITW and now the footprint, the reach
- 1:07:18Speaker 5: the power internal icon. So talk to us about that, like,
- 1:07:22Speaker 5: talk to me about stability in the market, how how
- 1:07:26Speaker 5: ITW has impacted.
- 1:07:28Speaker 4: You've seen it from both sides.
- 1:07:30Speaker 5: You saw it before, now you're part of this team,
- 1:07:32Speaker 5: so let's go through.
- 1:07:33Speaker 3: That a little bit.
- 1:07:34Speaker 17: Yeah, yeah, so it's been good. I get that question
- 1:07:36Speaker 17: a lot. I had it a couple of minutes ago
- 1:07:38Speaker 17: at the booth. You know, how's everything going since the
- 1:07:40Speaker 17: acquisition and we're over a year into it now, and
- 1:07:42Speaker 17: it's been pretty cool. You know, we took kind of
- 1:07:45Speaker 17: the best pieces of rx safe and you know, built
- 1:07:48Speaker 17: on the innovation and the technology and the kind of
- 1:07:51Speaker 17: customer backed innovation that rx safe had, and those principles
- 1:07:55Speaker 17: have kind of translated over to it TW. So ITW
- 1:07:58Speaker 17: really focuses on that seat customer backed innovation. And now
- 1:08:02Speaker 17: we're part of a family of a fortune two hundred company,
- 1:08:05Speaker 17: so you've got a lot more engineering resources. You've got
- 1:08:08Speaker 17: no worry about selling out to a private equity firm
- 1:08:10Speaker 17: or a VC, which was great for me personally and
- 1:08:13Speaker 17: the company. And it's really just been great to be
- 1:08:16Speaker 17: paired with Icon because we were a reseller Icon. We
- 1:08:19Speaker 17: used it with our existing technology for all those years,
- 1:08:22Speaker 17: fifteen sixteen years, and you know, it's kind of like,
- 1:08:25Speaker 17: you know, getting in with a company you already knew
- 1:08:29Speaker 17: versus somebody that was just out to squeeze every last
- 1:08:33Speaker 17: nickel out of you and bleed to drive.
- 1:08:34Speaker 5: So exactly, but guess what that's happening in our space.
- 1:08:38Speaker 5: And that's for another.
- 1:08:39Speaker 17: Podcast exactly, Yeah, the m and a podcast featuring a podcast.
- 1:08:44Speaker 5: All right, So with the Zembia being a specially drug show,
- 1:08:48Speaker 5: how has ARC safe and Icon served this space specifically?
- 1:08:51Speaker 17: Yeah, So on the icon side of the business, a
- 1:08:54Speaker 17: ton of specialty pharmacies have icons, particularly the newer model,
- 1:08:59Speaker 17: the ninety fourth thirty that we have. What that does
- 1:09:02Speaker 17: is it takes images of the tray. But a lot
- 1:09:05Speaker 17: of the specialty pharmacies are using it for unit vieus
- 1:09:07Speaker 17: items and imaging that and then that relays out to
- 1:09:11Speaker 17: a PB two function for a pharmacy owner, and then
- 1:09:13Speaker 17: it gives a good chain of custody for serialization as
- 1:09:17Speaker 17: well as auditing purposes on the arc Safe side of
- 1:09:20Speaker 17: the business specialty is huge for us in the pouch
- 1:09:23Speaker 17: packaging predominantly, and it's keeping those patients adhere and using
- 1:09:27Speaker 17: really good, thorough technology that we're checking multiple times, is
- 1:09:32Speaker 17: this the right drug that we're dispensing, and then finally
- 1:09:35Speaker 17: inspecting it before it goes out of the machine, providing
- 1:09:38Speaker 17: a real crisp, clear path to and adherent patient medication.
- 1:09:42Speaker 5: So what I really appreciate in my observance of RX
- 1:09:46Speaker 5: safe and when I heard about it tw in Icon,
- 1:09:52Speaker 5: I have to say I was nervous because I don't
- 1:09:54Speaker 5: want companies that I've worked with for years to get
- 1:09:58Speaker 5: watered down or changed in the way that they think
- 1:10:01Speaker 5: or your mission. And I'm not seeing any of that.
- 1:10:04Speaker 5: I'm seeing an enhancement to ARC safe and strength and power.
- 1:10:08Speaker 5: But before you became this bigger organization and have this
- 1:10:15Speaker 5: more depth to you, you are also extremely innovative, and
- 1:10:20Speaker 5: that part of it hasn't gone away either, So I
- 1:10:23Speaker 5: want to know what you're working on, something new that's
- 1:10:25Speaker 5: coming up, what's next for ARX safe in Icon.
- 1:10:27Speaker 17: Yeah, a lot of great stuff in the central fill model.
- 1:10:31Speaker 17: We've got a bunch of central fill site mail order sites,
- 1:10:34Speaker 17: some new robotics that we're working on for particularly in
- 1:10:38Speaker 17: the specialty mail order central fill space, as well as
- 1:10:41Speaker 17: software platforms that go along with that to drive everything
- 1:10:44Speaker 17: that would be fulfilled in one of those locations. Working
- 1:10:48Speaker 17: on a new revision of our legacy eighteen hundred robot
- 1:10:52Speaker 17: so we can get a more robust, new gen product
- 1:10:56Speaker 17: out to those thousands of customers that have those out
- 1:10:59Speaker 17: in the field. Not to say we're going to sunset
- 1:11:01Speaker 17: the old stuff, but we want to have a new
- 1:11:03Speaker 17: offering that is a lot more scalable than what we
- 1:11:05Speaker 17: have now. On the icon side of the book, we've
- 1:11:09Speaker 17: got OPV, which is optical pill verification, so taking a
- 1:11:12Speaker 17: true look at every individual tablet while it's on. They're
- 1:11:15Speaker 17: analyzing it, making sure it's accurate based on all the
- 1:11:18Speaker 17: different characteristics of the individual pill, versus just counting it
- 1:11:21Speaker 17: like everybody else does. Last one that we just released
- 1:11:26Speaker 17: was the rapid Card single dose at the MHA show.
- 1:11:30Speaker 17: Had fantastic reception. Going to be installing those pretty soon
- 1:11:34Speaker 17: here in short order in the next couple of months,
- 1:11:37Speaker 17: and it's just been gangbusters because there's not a lot
- 1:11:38Speaker 17: of options out there in the single dose market. It's
- 1:11:40Speaker 17: a couple of vendors and we've again listened to that
- 1:11:44Speaker 17: customer backed innovation and give them a product that they
- 1:11:46Speaker 17: want and they need.
- 1:11:48Speaker 5: So I want to take a pause for our listeners
- 1:11:51Speaker 5: just to understand something. Matt and the team have really
- 1:11:55Speaker 5: refined what it means to become a long term care
- 1:11:59Speaker 5: at home home pharmacy entity with all of the pieces
- 1:12:04Speaker 5: that go into the ingredients of really doing it the
- 1:12:06Speaker 5: right way. So when I think of specialty pharmacy, especially
- 1:12:10Speaker 5: pharmacies that are working to expand your markets, but then
- 1:12:13Speaker 5: you realize, hey, we have our own local market. There's
- 1:12:17Speaker 5: people that are living in their homes, they can't get
- 1:12:19Speaker 5: out of their homes that you know we need to
- 1:12:21Speaker 5: service them. I want you to reach out to the
- 1:12:23Speaker 5: RX Safe team, the Icon team, Matt specifically, because you've
- 1:12:27Speaker 5: really helped to blueprint how that fits and how that
- 1:12:30Speaker 5: works and ask questions how does our specialty pharmacy cater
- 1:12:34Speaker 5: to the long term care at home environment. Matt kind
- 1:12:38Speaker 5: of tell us a little bit about that whole concept
- 1:12:41Speaker 5: and how you guys have, Like I said, you guys
- 1:12:43Speaker 5: have built a really powerful boot blueprint.
- 1:12:45Speaker 17: Yeah, Well, I think the key is learning what the
- 1:12:47Speaker 17: market needs and then customizing to those needs with some
- 1:12:51Speaker 17: good solutions that we have not only from us, but
- 1:12:54Speaker 17: other partners in the industry. So whether it's a jerrymed
- 1:12:57Speaker 17: or it's a med Sense, or it's Paul Shall in
- 1:13:00Speaker 17: the LTC at Home Network or CPSN, we're plugged into
- 1:13:02Speaker 17: all these different channels that we can position you and
- 1:13:05Speaker 17: put you in the right direction. And we've done it
- 1:13:08Speaker 17: hundreds of times, so it's really tried and true. You know,
- 1:13:11Speaker 17: my business transformation team focuses on making sure the customer
- 1:13:15Speaker 17: successful post implementation. So whether that's a marketing need or
- 1:13:19Speaker 17: whether that's hey, how do I do this. I've never
- 1:13:22Speaker 17: serviced a group home before, I've never serviced a medical
- 1:13:25Speaker 17: at home patient before. How does that work? We really
- 1:13:28Speaker 17: would just want to offer you any type of solution
- 1:13:30Speaker 17: that'll make sure we get you in the right spot
- 1:13:32Speaker 17: that you need to be in.
- 1:13:33Speaker 5: Matt Gilbert, Arc Safe and Icon powerful partners of the
- 1:13:38Speaker 5: space of specially pharmacy pharmacy in general, and I want
- 1:13:41Speaker 5: to say thank you so much for the support that
- 1:13:43Speaker 5: you've given to the Pharmacy Podcast Network over the years.
- 1:13:46Speaker 17: Yeah, appreciate it. Great to be here and look forward
- 1:13:48Speaker 17: to seeing you again soon.
- 1:13:49Speaker 4: At some other conference that we'll run into each other.
- 1:13:52Speaker 3: Probably be next week. NOA, NOA,